Yes, I know why the price of the drug is so high. I also know as well as others why the stock price is at .175. Because in part the off-label market is not going to be a reality for years (in addition to the delays). That was the point of my post. I get the price point.
The reality is that at this current time, they now have a drug for a <10,000 patient population that his priced so high there will be virtually no off-label usage at approval. Why the priced the drug that high is irrelevant. The point being, this is not going to be the next Botox anytime soon. Maybe years down the road, but all the market cares about is what is happening now. Not 5 or 10 years from now. Shareholders already waited 9 years.
You said:
"cuv9900/vitiligo trials would not take 2 years to finish but could be done in just 2 or 3 months."
That's just plain hogwash and there is zero evidence of that. I have followed biotech for many years and there has never been a new compound that requires serious clinical trials and data - no matter the form - that took only 2 or 3 months to market. If that were the case, this stock would be close to $1 per share as a current valuation by the market.
Even if cuv9900 is a transdermal drug, it's not hand lotion or after shave. It's a serious drug that will rigorous rigorous testing before approval. This might be the compound that turns this into a Botox like blockbuster, but not anytime soon.
Aussie biotech investors aren't dummies.
Show me where the company said the cuv9900 trials would only take 2 or 3 months. So me another novel compound that only took 2 or 3 months of trials before the EMA or FDA were willing to approve it. Don't waste too much time looking for that evidence - it ain't out there.
CUV Price at posting:
17.5¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)